2025 Q4 -tulosraportti
39 päivää sitten
‧30 min
1,15 DKK/osake
Irtoamispäivä 19.3.
2,81%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 82 | - | - | ||
| 179 | - | - | ||
| 12 | - | - | ||
| 12 | - | - | ||
| 133 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
Vuosittainen yhtiökokous 2025 26.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9.3.Lundbeck is fully ready for crucial phase 3 study with important drug candidate ahead of schedule Close today at 11:25 ∙ MarketWire Premium Lundbeck B 1.06% The pharmaceutical company Lundbeck has enrolled and assigned treatment groups to the last patient in the phase 3 study Mascot with the drug candidate Amlenetug. The enrollment and preparation of the study have thus been completed ahead of schedule, the company states in an announcement Monday morning. The study, which has already been initiated across North America, Europe, Asia, and Australia, investigates the effect of Amlenetug in the rare neurological disease multiple system atrophy (MSA). Completing the randomization of a global phase 3 study in MSA is a significant achievement in this field, says Professor Günter Höglinger, who is leading the study. Advancing the development of a potential treatment for this undertreated disease addresses a critical unmet need for people living with MSA, he continues. Today, there are no approved treatments for MSA on the market, and Lundbeck therefore sees Amlenetug as a great opportunity in the company's pipeline. .\˙ MarketWire- ·16.2.AL Sydbank sees far more potential in Lundbeck than the share price reflects Close today at 10:50 ∙ MarketWire Lundbeck A 1,41% Lundbeck B 2,20% Lundbeck had overall a good close to a very strong 2025, and the pharmaceutical company also takes some of that momentum with it into 2026, where the immediate underlying forecast is completely approved. This is assessed by Søren Løntoft Hansen, who is a senior analyst at AL Sydbank. He also points out that the very big theme in the equity case - several threatening patent expirations on key drugs - should be well covered by Lundbeck's pipeline development over recent years. Therefore, the stock is unfairly held back right now, according to the assessment. The underlying 2026 forecast is approved - on the other hand, the currency headwind in 2026 is greater than expected, and that lowers our estimates. The positive development in the pipeline, which we have seen over the past year, should continue, in our assessment, to reduce investors' concern about patent cliffs later in the decade. In our view, Lundbeck's earnings potential is far from reflected in the current share price, writes Søren Løntoft Hansen in an analysis note. The bank therefore also maintains the positive recommendation "buy" for Lundbeck. For 2026, the Danish company expects revenue growth in local currencies of 5-8 pct. At the same time, Lundbeck aims for a growth in adjusted operating profit (EBITDA) of 4-12 pct. - also measured in local currency rates. Lundbeck's B-share rises Monday morning by 2,2 pct. to 39,90 kr. .\˙ MarketWire
- ·16.2.DNB Carnegie raises target price for Lundbeck to 53 Danish kroner (51), reiterates buy Close today at 08:35 ∙ Finwire
·9.2.Read last Friday on TV2 news that, according to "experts", Danish investors are, in plain words, idiots and should have a maximum of 1% Danish papers in their portfolio. Instead, one should seek towards IA and weapons. .Too late, and now a bubble.., but the "experts" convinced the microphone holder. I am one of the clowns who defensively and primarily invested in Danish papers and have had a return of 299% over the last 5 years. The "experts" naturally want customers in their shop for their expensive investment funds and other businesses with commissions, exchange fees, etc.
·17.2. · MuokattuInvestment funds are a waste of time. Furthermore, I hate mark-to-market taxation. The only thing I could imagine using an investment fund for was to get a foot into the bond market. Crazy to "recommend" AI right now, when short-term uncertainty is highest. Weapons I can understand, but I'm not in that, as I feel it's a train that's too late to jump on now. That being said, I'm trying to get beyond Danish stocks, as it bothers me when my portfolio starts to resemble an overweight in one specific market. The problem is just that the dollar is falling, so there's a risk that your American stocks will be eaten up by a falling dollar. I've been trying for a while now to find something in Asia that I would really like a bit more exposure to, but so far I've only found a single ETF (even though I don't like mark-to-market taxation:))
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
39 päivää sitten
‧30 min
1,15 DKK/osake
Irtoamispäivä 19.3.
2,81%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9.3.Lundbeck is fully ready for crucial phase 3 study with important drug candidate ahead of schedule Close today at 11:25 ∙ MarketWire Premium Lundbeck B 1.06% The pharmaceutical company Lundbeck has enrolled and assigned treatment groups to the last patient in the phase 3 study Mascot with the drug candidate Amlenetug. The enrollment and preparation of the study have thus been completed ahead of schedule, the company states in an announcement Monday morning. The study, which has already been initiated across North America, Europe, Asia, and Australia, investigates the effect of Amlenetug in the rare neurological disease multiple system atrophy (MSA). Completing the randomization of a global phase 3 study in MSA is a significant achievement in this field, says Professor Günter Höglinger, who is leading the study. Advancing the development of a potential treatment for this undertreated disease addresses a critical unmet need for people living with MSA, he continues. Today, there are no approved treatments for MSA on the market, and Lundbeck therefore sees Amlenetug as a great opportunity in the company's pipeline. .\˙ MarketWire
- ·16.2.AL Sydbank sees far more potential in Lundbeck than the share price reflects Close today at 10:50 ∙ MarketWire Lundbeck A 1,41% Lundbeck B 2,20% Lundbeck had overall a good close to a very strong 2025, and the pharmaceutical company also takes some of that momentum with it into 2026, where the immediate underlying forecast is completely approved. This is assessed by Søren Løntoft Hansen, who is a senior analyst at AL Sydbank. He also points out that the very big theme in the equity case - several threatening patent expirations on key drugs - should be well covered by Lundbeck's pipeline development over recent years. Therefore, the stock is unfairly held back right now, according to the assessment. The underlying 2026 forecast is approved - on the other hand, the currency headwind in 2026 is greater than expected, and that lowers our estimates. The positive development in the pipeline, which we have seen over the past year, should continue, in our assessment, to reduce investors' concern about patent cliffs later in the decade. In our view, Lundbeck's earnings potential is far from reflected in the current share price, writes Søren Løntoft Hansen in an analysis note. The bank therefore also maintains the positive recommendation "buy" for Lundbeck. For 2026, the Danish company expects revenue growth in local currencies of 5-8 pct. At the same time, Lundbeck aims for a growth in adjusted operating profit (EBITDA) of 4-12 pct. - also measured in local currency rates. Lundbeck's B-share rises Monday morning by 2,2 pct. to 39,90 kr. .\˙ MarketWire
- ·16.2.DNB Carnegie raises target price for Lundbeck to 53 Danish kroner (51), reiterates buy Close today at 08:35 ∙ Finwire
- ·9.2.Read last Friday on TV2 news that, according to "experts", Danish investors are, in plain words, idiots and should have a maximum of 1% Danish papers in their portfolio. Instead, one should seek towards IA and weapons. .Too late, and now a bubble.., but the "experts" convinced the microphone holder. I am one of the clowns who defensively and primarily invested in Danish papers and have had a return of 299% over the last 5 years. The "experts" naturally want customers in their shop for their expensive investment funds and other businesses with commissions, exchange fees, etc.·17.2. · MuokattuInvestment funds are a waste of time. Furthermore, I hate mark-to-market taxation. The only thing I could imagine using an investment fund for was to get a foot into the bond market. Crazy to "recommend" AI right now, when short-term uncertainty is highest. Weapons I can understand, but I'm not in that, as I feel it's a train that's too late to jump on now. That being said, I'm trying to get beyond Danish stocks, as it bothers me when my portfolio starts to resemble an overweight in one specific market. The problem is just that the dollar is falling, so there's a risk that your American stocks will be eaten up by a falling dollar. I've been trying for a while now to find something in Asia that I would really like a bit more exposure to, but so far I've only found a single ETF (even though I don't like mark-to-market taxation:))
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 82 | - | - | ||
| 179 | - | - | ||
| 12 | - | - | ||
| 12 | - | - | ||
| 133 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
Vuosittainen yhtiökokous 2025 26.3.2025 |
2025 Q4 -tulosraportti
39 päivää sitten
‧30 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
Vuosittainen yhtiökokous 2025 26.3.2025 |
1,15 DKK/osake
Irtoamispäivä 19.3.
2,81%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9.3.Lundbeck is fully ready for crucial phase 3 study with important drug candidate ahead of schedule Close today at 11:25 ∙ MarketWire Premium Lundbeck B 1.06% The pharmaceutical company Lundbeck has enrolled and assigned treatment groups to the last patient in the phase 3 study Mascot with the drug candidate Amlenetug. The enrollment and preparation of the study have thus been completed ahead of schedule, the company states in an announcement Monday morning. The study, which has already been initiated across North America, Europe, Asia, and Australia, investigates the effect of Amlenetug in the rare neurological disease multiple system atrophy (MSA). Completing the randomization of a global phase 3 study in MSA is a significant achievement in this field, says Professor Günter Höglinger, who is leading the study. Advancing the development of a potential treatment for this undertreated disease addresses a critical unmet need for people living with MSA, he continues. Today, there are no approved treatments for MSA on the market, and Lundbeck therefore sees Amlenetug as a great opportunity in the company's pipeline. .\˙ MarketWire
- ·16.2.AL Sydbank sees far more potential in Lundbeck than the share price reflects Close today at 10:50 ∙ MarketWire Lundbeck A 1,41% Lundbeck B 2,20% Lundbeck had overall a good close to a very strong 2025, and the pharmaceutical company also takes some of that momentum with it into 2026, where the immediate underlying forecast is completely approved. This is assessed by Søren Løntoft Hansen, who is a senior analyst at AL Sydbank. He also points out that the very big theme in the equity case - several threatening patent expirations on key drugs - should be well covered by Lundbeck's pipeline development over recent years. Therefore, the stock is unfairly held back right now, according to the assessment. The underlying 2026 forecast is approved - on the other hand, the currency headwind in 2026 is greater than expected, and that lowers our estimates. The positive development in the pipeline, which we have seen over the past year, should continue, in our assessment, to reduce investors' concern about patent cliffs later in the decade. In our view, Lundbeck's earnings potential is far from reflected in the current share price, writes Søren Løntoft Hansen in an analysis note. The bank therefore also maintains the positive recommendation "buy" for Lundbeck. For 2026, the Danish company expects revenue growth in local currencies of 5-8 pct. At the same time, Lundbeck aims for a growth in adjusted operating profit (EBITDA) of 4-12 pct. - also measured in local currency rates. Lundbeck's B-share rises Monday morning by 2,2 pct. to 39,90 kr. .\˙ MarketWire
- ·16.2.DNB Carnegie raises target price for Lundbeck to 53 Danish kroner (51), reiterates buy Close today at 08:35 ∙ Finwire
- ·9.2.Read last Friday on TV2 news that, according to "experts", Danish investors are, in plain words, idiots and should have a maximum of 1% Danish papers in their portfolio. Instead, one should seek towards IA and weapons. .Too late, and now a bubble.., but the "experts" convinced the microphone holder. I am one of the clowns who defensively and primarily invested in Danish papers and have had a return of 299% over the last 5 years. The "experts" naturally want customers in their shop for their expensive investment funds and other businesses with commissions, exchange fees, etc.·17.2. · MuokattuInvestment funds are a waste of time. Furthermore, I hate mark-to-market taxation. The only thing I could imagine using an investment fund for was to get a foot into the bond market. Crazy to "recommend" AI right now, when short-term uncertainty is highest. Weapons I can understand, but I'm not in that, as I feel it's a train that's too late to jump on now. That being said, I'm trying to get beyond Danish stocks, as it bothers me when my portfolio starts to resemble an overweight in one specific market. The problem is just that the dollar is falling, so there's a risk that your American stocks will be eaten up by a falling dollar. I've been trying for a while now to find something in Asia that I would really like a bit more exposure to, but so far I've only found a single ETF (even though I don't like mark-to-market taxation:))
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 82 | - | - | ||
| 179 | - | - | ||
| 12 | - | - | ||
| 12 | - | - | ||
| 133 | - | - |
Välittäjätilasto
Dataa ei löytynyt